Lung transplantation in children following bone marrow transplantation: A multi-center experience

S. Yousef, C. Benden, D. Boyer, O. Elidemir, T. Frischer, S. Goldfarb, G. Lopez-Mitnik, G. Mallory, G. Visner, G. Westall, M. G. Schecter

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Allogenic BMT has been successfully performed as a treatment for hematologic diseases with an expected long-term survival. This survival is truncated by respiratory complications including airway obstruction especially BO. Chronic GVHD has been reported to precede almost all cases reported. LTx has become a therapeutic life-saving option for patients with end-stage lung disease that maybe offered for the treatment of GVHD. We report a multi-center experience of pediatric LTx following BMT in 11 patients age- and gender-matched with 11 controls who received LTx for end-stage lung disease secondary to CF. Overall death was 36.4% over a follow-up period of 19 months (range 3-36 months) for the cases and 27.3% for the control group followed for 17 months (range 8-32 months). Median FEV1 one yr post-transplant for the cases was 78% predicted compared with 67.3% predicted for the controls. The median for episodes of infection was comparable at a median of one episode per patient through the entire follow-up period among both groups. Acute rejection episodes were significantly higher in the control group with a median of one episode per patient in the control group compared to none within the cases. Our data suggest that LTx may be a valuable therapeutic option for children with end-stage lung disease post-BMT with comparable survival outcome to that after LTx in children for other indications such as CF. Hospital stay was significantly longer in our case group. Infection rate was comparable between groups albeit type of infection varied. Significantly and of interest is that acute rejection episodes were non-existent in these cases.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalPediatric Transplantation
Volume17
Issue number3
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Lung Transplantation
Bone Marrow Transplantation
Lung Diseases
Control Groups
Survival
Infection
Hematologic Diseases
Airway Obstruction
Therapeutics
Length of Stay
Pediatrics
Transplants

Keywords

  • pediatric lung transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Yousef, S., Benden, C., Boyer, D., Elidemir, O., Frischer, T., Goldfarb, S., ... Schecter, M. G. (2013). Lung transplantation in children following bone marrow transplantation: A multi-center experience. Pediatric Transplantation, 17(3), 231-236. https://doi.org/10.1111/petr.12023

Lung transplantation in children following bone marrow transplantation : A multi-center experience. / Yousef, S.; Benden, C.; Boyer, D.; Elidemir, O.; Frischer, T.; Goldfarb, S.; Lopez-Mitnik, G.; Mallory, G.; Visner, G.; Westall, G.; Schecter, M. G.

In: Pediatric Transplantation, Vol. 17, No. 3, 01.05.2013, p. 231-236.

Research output: Contribution to journalArticle

Yousef, S, Benden, C, Boyer, D, Elidemir, O, Frischer, T, Goldfarb, S, Lopez-Mitnik, G, Mallory, G, Visner, G, Westall, G & Schecter, MG 2013, 'Lung transplantation in children following bone marrow transplantation: A multi-center experience', Pediatric Transplantation, vol. 17, no. 3, pp. 231-236. https://doi.org/10.1111/petr.12023
Yousef, S. ; Benden, C. ; Boyer, D. ; Elidemir, O. ; Frischer, T. ; Goldfarb, S. ; Lopez-Mitnik, G. ; Mallory, G. ; Visner, G. ; Westall, G. ; Schecter, M. G. / Lung transplantation in children following bone marrow transplantation : A multi-center experience. In: Pediatric Transplantation. 2013 ; Vol. 17, No. 3. pp. 231-236.
@article{1d0bebc45bc94f52a8f1d5095719362d,
title = "Lung transplantation in children following bone marrow transplantation: A multi-center experience",
abstract = "Allogenic BMT has been successfully performed as a treatment for hematologic diseases with an expected long-term survival. This survival is truncated by respiratory complications including airway obstruction especially BO. Chronic GVHD has been reported to precede almost all cases reported. LTx has become a therapeutic life-saving option for patients with end-stage lung disease that maybe offered for the treatment of GVHD. We report a multi-center experience of pediatric LTx following BMT in 11 patients age- and gender-matched with 11 controls who received LTx for end-stage lung disease secondary to CF. Overall death was 36.4{\%} over a follow-up period of 19 months (range 3-36 months) for the cases and 27.3{\%} for the control group followed for 17 months (range 8-32 months). Median FEV1 one yr post-transplant for the cases was 78{\%} predicted compared with 67.3{\%} predicted for the controls. The median for episodes of infection was comparable at a median of one episode per patient through the entire follow-up period among both groups. Acute rejection episodes were significantly higher in the control group with a median of one episode per patient in the control group compared to none within the cases. Our data suggest that LTx may be a valuable therapeutic option for children with end-stage lung disease post-BMT with comparable survival outcome to that after LTx in children for other indications such as CF. Hospital stay was significantly longer in our case group. Infection rate was comparable between groups albeit type of infection varied. Significantly and of interest is that acute rejection episodes were non-existent in these cases.",
keywords = "pediatric lung transplantation",
author = "S. Yousef and C. Benden and D. Boyer and O. Elidemir and T. Frischer and S. Goldfarb and G. Lopez-Mitnik and G. Mallory and G. Visner and G. Westall and Schecter, {M. G.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1111/petr.12023",
language = "English",
volume = "17",
pages = "231--236",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Lung transplantation in children following bone marrow transplantation

T2 - A multi-center experience

AU - Yousef, S.

AU - Benden, C.

AU - Boyer, D.

AU - Elidemir, O.

AU - Frischer, T.

AU - Goldfarb, S.

AU - Lopez-Mitnik, G.

AU - Mallory, G.

AU - Visner, G.

AU - Westall, G.

AU - Schecter, M. G.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Allogenic BMT has been successfully performed as a treatment for hematologic diseases with an expected long-term survival. This survival is truncated by respiratory complications including airway obstruction especially BO. Chronic GVHD has been reported to precede almost all cases reported. LTx has become a therapeutic life-saving option for patients with end-stage lung disease that maybe offered for the treatment of GVHD. We report a multi-center experience of pediatric LTx following BMT in 11 patients age- and gender-matched with 11 controls who received LTx for end-stage lung disease secondary to CF. Overall death was 36.4% over a follow-up period of 19 months (range 3-36 months) for the cases and 27.3% for the control group followed for 17 months (range 8-32 months). Median FEV1 one yr post-transplant for the cases was 78% predicted compared with 67.3% predicted for the controls. The median for episodes of infection was comparable at a median of one episode per patient through the entire follow-up period among both groups. Acute rejection episodes were significantly higher in the control group with a median of one episode per patient in the control group compared to none within the cases. Our data suggest that LTx may be a valuable therapeutic option for children with end-stage lung disease post-BMT with comparable survival outcome to that after LTx in children for other indications such as CF. Hospital stay was significantly longer in our case group. Infection rate was comparable between groups albeit type of infection varied. Significantly and of interest is that acute rejection episodes were non-existent in these cases.

AB - Allogenic BMT has been successfully performed as a treatment for hematologic diseases with an expected long-term survival. This survival is truncated by respiratory complications including airway obstruction especially BO. Chronic GVHD has been reported to precede almost all cases reported. LTx has become a therapeutic life-saving option for patients with end-stage lung disease that maybe offered for the treatment of GVHD. We report a multi-center experience of pediatric LTx following BMT in 11 patients age- and gender-matched with 11 controls who received LTx for end-stage lung disease secondary to CF. Overall death was 36.4% over a follow-up period of 19 months (range 3-36 months) for the cases and 27.3% for the control group followed for 17 months (range 8-32 months). Median FEV1 one yr post-transplant for the cases was 78% predicted compared with 67.3% predicted for the controls. The median for episodes of infection was comparable at a median of one episode per patient through the entire follow-up period among both groups. Acute rejection episodes were significantly higher in the control group with a median of one episode per patient in the control group compared to none within the cases. Our data suggest that LTx may be a valuable therapeutic option for children with end-stage lung disease post-BMT with comparable survival outcome to that after LTx in children for other indications such as CF. Hospital stay was significantly longer in our case group. Infection rate was comparable between groups albeit type of infection varied. Significantly and of interest is that acute rejection episodes were non-existent in these cases.

KW - pediatric lung transplantation

UR - http://www.scopus.com/inward/record.url?scp=84876708701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876708701&partnerID=8YFLogxK

U2 - 10.1111/petr.12023

DO - 10.1111/petr.12023

M3 - Article

C2 - 23217003

AN - SCOPUS:84876708701

VL - 17

SP - 231

EP - 236

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 3

ER -